ClinicalTrials.gg
CompletedNCT05377580Updated Nov 19, 2025

A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis

A Phase 2 interventional study of Period 1 IBI112 Placebo and Period 2 IBI112 dose 3 in Ulcerative Colitis (UC), sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 183 studies in Colitis, Ulcerative with a site in China — 72 open to participants now, 95 under way, 25 of them phase 3. Colitis, Ulcerative · China.

Enrollment
59th of 135
150 · median 120
Started
2022
with 13 others
Phase 2
34 of 183
14 open now
Registered
73rd of 183
by date

Among the 183 studies in Colitis, Ulcerative with a site in China, this one is the 59th largest by enrollment of the 135 interventional ones that give a count, is one of 14 that started in 2022, is one of 34 in phase 2, and was the 73rd registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

72 of the 183 studies in Colitis, Ulcerative with a site in China are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 183 studies in Colitis, Ulcerative with a site in China, or all of them as a file.
02

Study summary

To evaluate the efficacy of IBI112 induction therapy in patients with moderate and severe active Ulcerative Colitis (UC) to achieve clinical remission.

Read the detailed description

This is a phase 2 randomized,double-blind, placebo-controlled study to evaluate the efficacy and safety of IBI112 induction and maintenance therapy in subjects with moderate to severe active ulcerative colitis

03

Conditions studied

  • Ulcerative Colitis (UC)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of ulcerative colitis at least 3 months ago, including endoscopy evidence supporting UC and histopathological evidence supporting UC diagnosis;
  2. Patients with moderate to severe ulcerative colitis, defined as modified Mayo Score ≥4 and endoscopic score ≥2;
  3. Subject must have received at least one prior treatment or first use of a biological agent:

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of ischemic colitis, infectious colitis, radiation colitis, microscopic colitis, uncertain colitis, etc., or crohn's disease;
  2. UC lesions were limited to rectum or involved colon \< 15cm;
  3. Evidence of toxic hirschsprung's disease was found during screening;
  4. History or evidence of atypical hyperplasia of the colon, adenomatous polyps (not removed before entering the study) or gastrointestinal tumors;
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Period 2 IBI112 dose 4

    Drug: Period 2 IBI112 dose 4

  • Placebo comparator
    Period 1 IBI112 Placebo

    Drug: Period 1 IBI112 Placebo

  • Experimental
    Period 2 IBI112 dose 3

    Drug: Period 2 IBI112 dose 3 · Drug: Period 2 IBI112 Placebo

  • Experimental
    Period 1 IBI112 dose 2

    Drug: Period 1 IBI112 dose 2

  • Placebo comparator
    Period 2 IBI112 Placebo

    Drug: Period 2 IBI112 Placebo

  • Experimental
    Period 1 IBI112 dose 1

    Drug: Period 1 IBI112 Placebo · Drug: Period 1 IBI112 dose 1

Interventions

  • DrugPeriod 1 IBI112 Placebo

    Intravenous Injection

    Also known as: Placebo

  • Subcutaneous injections

    Also known as: IBI112 dose 3

  • Intravenous Injection

    Also known as: IBI112 dose 1

  • Intravenous Injection

    Also known as: IBI112 dose 2

  • Intravenous Injection

    Also known as: IBI112 dose 4

  • DrugPeriod 2 IBI112 Placebo

    Subcutaneous injections

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Evaluate the effectiveness of IBI112 in inducing clinical remission in patients with moderately to severely active ulcerative colitis (UC)

    Percentage of subjects who achieved clinical remission at week 12.

    Time frame: week 12

Secondary outcomes

  1. The proportion of participants achieving a clinical response at Week 12.

    Clinical response is defined as a relative decrease from baseline in the modified Mayo score of ≥30% and ≥2 points, along with a relative decrease in the rectal bleeding subscore of ≥1 point or an absolute subscore of 0 or 1.

    Time frame: week 12

  2. The proportion of participants achieving symptomatic relief at Week 12.

    Symptomatic relief is defined as a stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0.

    Time frame: week 12

  3. The proportion of participants achieving endoscopic remission at Week 12.

    Endoscopic remission is defined as an endoscopic subscore of 0 or 1 within the modified Mayo score.

    Time frame: week 12

  4. The proportion of participants achieving mucosal healing at Week 12.

    Mucosal healing is defined as endoscopic remission, which means an endoscopic subscore of 0 or 1 within the modified Mayo score, and central Geboes histopathological index remission.

    Time frame: week 12

  5. The proportion of participants achieving clinical remission at Week 52 during the maintenance treatment period.

    Time frame: week 52

  6. The proportion of participants achieving clinical response at Week 52 during the maintenance treatment period.

    Time frame: week 52

  7. The proportion of participants achieving symptomatic relief at Week 52 during the maintenance treatment period.

    Time frame: week 52

  8. The proportion of participants achieving mucosal healing at Week 52 during the maintenance treatment period.

    Time frame: week 52

  9. The proportion of participants achieving endoscopic remission at Week 52 during the maintenance treatment period.

    Time frame: week 52

  10. The change from baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) scores at Week 12, Week 52 during the maintenance treatment period, and Weeks 24 and 64 during the extension treatment period.

    Time frame: Week 12, Week 52,Weeks 24 and 64

  11. The change from baseline in the 36-item Short Form Health Survey (SF-36) scores at Week 12, Week 52 during the maintenance treatment period, and Weeks 24 and 64 during the extension treatment period.

    Time frame: Week 12, Week 52,Weeks 24 and 64

07

Study locations

1 site
  • First Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong 510080, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Jun 2024, 23 months.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 23 months is below that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2022
First posted
May 17, 2022
StartActual
Jul 1, 2022
Primary completionActual
Jun 21, 2024
CompletionActual
Aug 7, 2025
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05377580
Responsible party
Sponsor
First posted
May 17, 2022
Start date
Jul 1, 2022
Primary completion
Jun 21, 2024
Completion
Aug 7, 2025
Last update
Nov 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI112

Start the discussion